atectura breezhaler
novartis europharm limited - indacaterol acetate, mometasone furoate - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
dexamethasone phosphate hameln 4 mg/ml injektioneste, liuos
hameln pharma gmbh - dexamethasone sodium phosphate - injektioneste, liuos - 4 mg/ml - deksametasoni
inomax
linde healthcare ab - typpioksidi - hypertension, pulmonary; respiratory insufficiency - muut hengitysteiden tuotteet - inomax, yhdessä potilaan hengityksen tukeminen ventilaation avulla ja muita asianmukaisia aktiivisia aineita, on ilmoitettu:hoitoon vastasyntyneiden ≥34 raskausviikolla kanssa hypoksinen hengityksen vajaatoiminta ja siihen liittyviä kliinisiä tai kaikukardiografisia todisteita pulmonaalihypertensiosta, jotta voidaan parantaa hapetusta ja vähentää tarvetta ecmo;osana hoito peri - ja postoperatiivisen pulmonaalihypertension hoidossa aikuisilla ja vastasyntyneet, imeväisikäiset ja pikkulapset, lapset ja nuoret, iältään 0-17 vuotta yhdessä sydänkirurgia, jotta valikoivasti vähentää keuhkovaltimon painetta ja parantamaan oikean kammion toimintaa ja hapetusta.
diprosalic 0,5 mg/g + 30 mg/g voide
n.v. organon - betamethasone dipropionate, salicylic acid - voide - 0,5 mg/g + 30 mg/g - beetametasoni
diprosalic 0,5 mg/g + 20 mg/g liuos iholle
n.v. organon - betamethasone dipropionate, salicylic acid - liuos iholle - 0,5 mg/g + 20 mg/g - beetametasoni
elocon 0.1 % voide
n.v. organon - mometasone furoate - voide - 0.1 % - mometasoni
elocon 0.1 % emulsiovoide
n.v. organon - mometasone furoate - emulsiovoide - 0.1 % - mometasoni
elocon 0.1 % liuos iholle
n.v. organon - mometasone furoate - liuos iholle - 0.1 % - mometasoni
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - karsinooma, squamous cell - antineoplastiset aineet - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.